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Primary Endpoint Results of the TAXUS Liberte Post-Approval Study
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Heart Institute, Ashland, KY, 3Our Lady of Lourdes Medical Center, Camden, NJ,
4Tyler Cardiac and Endovascular Center, Tyler, TX, 5United Heart & Vascular
Clinic, St. Paul, MN, 6Baptist Medical Center, Jacksonville, FL, 7Eli Lilly and
Company, Indianapolis, IN, 8Boston Scientiﬁc, Natick, MA, 9Boston Scientiﬁc
Corporation, Marlborough, MA, 10Lenox Hill Hospital, New York, NY
Background: The TAXUS Liberte Post-Approval Study (TL-PAS) is a prospective,
multicenter US registry which enrolled 4199 patients, of which 1592 were deﬁned as
“on-label”, i.e. treated as per the FDA-approved labeling for TL. Unique features of
this registry include the TL stent and exclusive use of at least 12 months of prasugrel
as part of a dual antiplatelet therapy (DAPT) strategy after stenting. Previous work
demonstrated that in-hospital major adverse cardiac events (MACE) were favorable
when compared to the TAXUS Express ARRIVE registries, which utilized the
TAXUS Express (TE) stent and clopidogrel.
Methods: Patients were enrolled at 82 sites between December 2009 - January 2012.
After stenting, patients were prescribed aspirin and prasugrel (5 mg or 10 mg doses, as
appropriate) for 12 months. Statistical testing was performed to determine if the
primary endpoint of 12-month cardiac death or MI for the TL stent was non-inferior to
the TE stent. A total of 2463 “on-label” patients receiving the TL stent from the
TL-PAS (n¼1592) and TAXUS ATLAS Workhorse studies (WH; n¼871) were
compared to the 3676 "on-label" TE-treated patients in the control arm of TAXUS
ATLAS WH (n¼978) and ARRIVE 1/2 registries (n¼2698). Secondary outcomes
including MACE (death, MI or target vessel failure), stent thrombosis and GUSTO
moderate/severe bleeding are reported in the overall and "on-label" populations of
TL-PAS.
Results: Rates of the primary endpoint of cardiac death and MI were 3.0% (108/3554)
with TE and 2.2% (52/2384) with TL; thus the criteria for non-inferiority were met
(p<0.0001). Low rates of other adverse cardiac outcomes and bleeding were observed




3.0% (108/3554) 2.2% (52/2384)
TAXUS Liberte PAS TAXUS Liberte PAS
Overall On-label
(N¼4199 Patients)d (N¼1592 Patients)e
MACE 7.2% (295) 4.8% (74)
TVF 6.3% (259) 4.6% (71)
Death 1.3% (55) 0.6% (9)
Cardiac Death 0.9% (37) 0.2% (3)
Cardiac Death or MI 2.1% (87) 0.9% (14)
MI 1.4% (57) 0.7% (11)
TVR 5.8% (236) 4.2% (65)
Stent Thrombosis (Protocol) 0.9% (36) 0.3% (4)
Major Bleeding (GUSTO
moderate/severe)
3.6% (146) 3.0% (47)
A: Non-inferiority comparison p<0.0001; binary rates; B: on label TE-treated patients from the
control arm of the TAXUS ATLAS Workhorse Clinical Trial and the ARRIVE 1 and 2 registries; C:
on-label TL-treated patients in the TAXUS ATLAS Workhorse Clinical Trial and TL-PAS; D: all
patients enrolled in TL-PAS; KM estimates; E: on-label patients
B54 JACC Vol 62/18/Suppl B j October 27–November 1, 2013Conclusions: The 1 year TL-PAS primary endpoint results show low rates of cardiac
death/ MI (as well as overall MACE, stent thrombosis, and bleeding) utilizing
a strategy of TAXUS Liberté stent and DAPT including prasugrel.
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Beneﬁt of Large Size Bare Metal Stent in Long Term Observation of Real World
Large Population
Hirotsugu Mitsuhashi1, Dean Traboulsi2, Meril Knudtson2
1St Lukes International Hospital, Tokyo, Tokyo, 2University of Calgary Foothills
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Background: Drug eluting stent (DES) has been vastly used for percutaneous coro-
nary intervention (PCI), but its late restenosis has been reported and long term beneﬁt
has been questionable especially in large size stent.
Methods: Consecutive 12276 patients who received PCI between 2004 and 2011
were included in the study. Patients were divided into 4 groups: small bare metal stent
(BMS), large BMS, small DES and large DES group depending on kind and size of
implanted stents. Small stent was deﬁned as its size was 3.25mm or smaller. Large
stent was deﬁned as the others. Selection of each stent was decided by operators.
Average observation period was 1488 days. Shortest and longest observation periods
were 1 and 2647 days. All-cause mortality and target lesion revascularization (TLR)
rate was compared. Hazard ratio (HR) of morality and TLR in small DES and large
BMS compared to small BMS, and in large DES compared to large BMS and its 95%
conﬁdence intervals (CIs) were calculated with multivariate Cox regression analysis
adjusted for patient background.
Results: 522, 2096, 3328 and 394 patients were included in small BMS, small
DES, large BMS and large DES group. Mortality was observed in each group was
475 (7.3%), 128 (6.1%), 202 (6.1%) and 23 (5.8%) patients. TLR was observed in
332 (5.1%), 112 (5.3%), 134 (4.0%) and 32 (8.1%) patients. HRs of mortality
compared to small BMS in small DES, large BMS and large DES were 0.99 (95%
CI: 0.80-1.22, p ¼ 0.92), 0.84 (95% CI: 0.70-1.01, p ¼ 0.068) and 0.80 (95% CI:
0.48-1.33, p ¼ 0.39). HR of mortality in large DES compared to large BMS was
1.01 (95% CI: 0.60-1.72, p ¼ 0.97). HRs of TLR compared to small BMS in small
DES, large BMS and large DES were 1.04 (95% CI: 0.83-1.29, p ¼ 0.75), 0.72
(95% CI: 0.59-0.88, p ¼ 0.002), and 1.40 (95% CI: 0.97-2.03, p ¼ 0.070). HR of
TLR compared to large BMS in large DES was 1.83 (95% CI: 1.24-2.70,
p ¼ 0.002).
Conclusions: No signiﬁcant difference was observed in mortality. Large BMS
signiﬁcantly reduced TLR compared to small BMS. Large DES signiﬁcantly increased
TLR compared to large BMS. Large BMS showed lowest TLR rate among all groups
tested.
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Background: The aim of this registry is to evaluate the clinical performance of
a new generation Sirolimus eluting stent system (Osiro) in a large patient pop-
ulation in standard clinical care. The Osiro is a unique hybrid solution that
combines passive and active components. PROBIO passive coating encapsulates
the stent and minimizes interaction between the metal stent and surrounding tissue.
BIOlute active coating contains a highly biocompatible and biodegradable
polymer.
Methods: Between August 2011 and March 2012, 1,356 subjects were enrolled
consecutively in this international, multicentric BIOFLOW-III all-comers registry
using the Osiro Sirolimus eluting stent. Primary endpoint is Target Lesion Failure
(TLF) at twelve months follow-up. Pre-speciﬁed subgroups were diabetes, small
vessels, chronic total occlusion and acute myocardial infarction.
Results: Nine hundred seventy one men (72%) and three hundred eighty ﬁve
women were enrolled at 43 sites in 14 countries. The mean age was 66.1  10.7,
ranging from 29-91 years. Based on our preliminary data, the majority of subjects
presented with hypertension 76%, hypercholesteremia 60%, smoker 55%, and
diabetes 30% 48% of all stented vessels had a diameter 2.75mm, 4% presented
with chronic total occlusion. Eleven percent of the subjects experienced unstable
angina, 47% stable angina. Acute MI was seen in 33% of the subjects (NSTEMI
22%, STEMI 11%). The portion of elderly subjects ( 75 years) is represented by
25%. Ninety seven percent (1,321) follow up compliance at six months and ninety
ﬁve percent (1,289) at twelve months were achieved. An unbiased patient pop-
ulation was seen in the registry with more than 52% type B2/C lesions. Moderate
and severe calciﬁcation was observed in 31%. The Osiro hybrid stent system
demonstrated excellent device (98.7%) and procedure success (98.2%). In thisj TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMall-comers setting a TLF rate of 4.7% was observed within the ﬁrst 12 months. The
low TLF rate was also conﬁrmed for pre-deﬁned subgroups: diabetics, acute MI,
small vessel and CTO.
Conclusions: Preliminary data in this "real world" population demonstrates a low TLF
rate comparable to other state of the art DES at 6- and 12-months.
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African-American Race Is Associated with Less Use of Drug-Eluting Stents
Michael A. Gaglia1, David M. Shavelle2, Jiken Bhatt1, Han Tun1, Anilkumar Mehra1,
Ray V. Matthews1, Leonardo C. Clavijo1
1University of Southern California, Los Angeles, CA, 2University of Southern
California, Los Angeles, CA
Background: Guidelines for percutaneous coronary intervention (PCI) specify that
drug-eluting stents (DES) should not be used in patients unable to comply with
prolonged dual antiplatelet therapy. In addition, previous research has suggested that
insurance status is associated with receipt of DES. The impact of socioeconomic
factors upon use of DES has not been previously studied in an underserved population
presenting to a public hospital for PCI.
Methods: Patients undergoing PCI with stenting at Los Angeles County Hospital
were retrospectively analyzed. Multivariable logistic regression was performed, with
receipt of 1 DES as the outcome of interest. Insurance type was categorized as
uninsured, incarcerated, Medicare, Medicaid, and private, based upon primary
insurance at discharge. Race was obtained by patient response on admission and then
deﬁned as Hispanic, African-American, or other (Caucasian, Asian, Native American,
and other) for purposes of comparison.
Results: Among 2763 patients who underwent PCI with stenting, 62.8% received 1
DES. In regards to insurance type, 33.2% were uninsured, 1.7% incarcerated, 22.5%
Medicare, 28.5% Medicaid, and 14.1% private. Self-reported race was 45.4%
Hispanic, 26.8% Caucasian, 11.8% Asian, 6.7% African-American, 0.3% Native
American, and 9.0% other. Patients receiving DES had higher median income by
zipcode, $52835 v. $50432 (p¼0.007). After multivariable adjustment, African-
American and Medicare patients were less likely to receive DES; Medicaid and
uninsured patients were more likely (Table).
Conclusions: Uninsured and government-insured patients were as, or more, likely to
receive DES as patients with private insurance, but African-American patients were
less likely to receive DES. Reasons for this disparity are poorly understood; future
research should focus upon physician perceptions of patient compliance.Variable Odds Ratio 95% CI p value
History of PCI 1.43 1.17-1.74 <0.001
History of CABG 1.54 1.16-2.04 0.003
Current smoking 0.68 0.54-0.85 <0.001
STEMI 0.41 0.31-0.53 <0.001
NSTEMI or unstable angina 1.23 1.01-1.49 0.04
Shock 0.43 0.29-0.63 <0.001
Baseline hematocrit (per 5%) 1.03 1.01-1.05 <0.001
Stent length (per 5 mm) 1.2 1.16-1.23 <0.001
African-American 0.57 0.40-0.82 0.002
Hispanic 0.87 0.72-1.05 0.15
Medicare 0.71 0.52-0.95 0.02
Medicaid 1.49 1.11-2.00 0.008
Incarcerated 0.54 0.27-1.08 0.08








J-DESsERT 3-Year Outcomes: Largest randomized trial stratiﬁed by diabetes
mellitus presence, comparing sirolimus and paclitaxel eluting stents.
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Background: Japan-Drug Eluting Stents Evaluation; a Randomized Trial
(J-DESsERT) was the largest randomized trial conducted to directly compare theJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrefﬁcacy of sirolimus-eluting stents (SES) over paclitaxel-eluting stents (PES). The aim
of this investigation was to validate the difference in the efﬁcacy and safety of SES vs.
PES over 2 and 3-year follow-up periods.However, this phenomenon has not been
conﬁrmed by well-designed, large scale randomized controlled trials.
Methods: In this largest prospective and multicenter trial, patients were randomized
1:1 to coronary stenting with either SES or PES. Lesion lengths were 46mm with
vessel diameters from 2.5mm to 3.75 mm. Randomization was stratiﬁed based on
the presence or absence of diabetes mellitus (DM). Up to 3 lesions in a maximum of 2
targeted vascular branches could be treated at a time. Target vessel failure (TVF) and
major adverse cardiac cerebrovascular events (MACCE) deﬁned as all death, MI,
TVR, and cerebrovascular accident at 2 years in all populations, and TVF at 3 years
for the DM subset was assessed.
Results: A total of 3,533 patients including 1,724 DM patients were enrolled in this
trial. There was no signiﬁcant difference in patient-characteristics except for the
incidence of stable angina. 65.1% of lesions were B2/C. More than 75% of coronary
artery lesions were assessed via intravascular ultrasound and technical success of stent
deployment was obtained in 98.1% of lesions. PES TVF non-inferiority was not
demonstrated when compared to SES (SES 4.5 % vs PES 6.4%, p¼0.23). SES TVF
was lower than PES in the DM subset. Additionally, SES TVF was lower than PES at
8 months in the DM subset. SES TVF superiority over PES was demonstrated at 12
months in both the DM subset as well as in the entire patient population. (SES 6.0 %
vs PES 9.0 %, p<0.01, SES 7.6% vs PES 10.6% p¼0.03, respectively.) The incidence
of myocardial infarction, stroke, and intervention to remote segments, was almost
identical in both groups.
Conclusions: Final outcomes as demonstrated by 3 year follow-up will be presented
at TCT 2013. This trial will provide deep insight for the long-term efﬁcacy of these
two different types of DES.
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Clinical Outcome of Complex Patients Treated With Second-Generation
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Background: Contemporary second-generation drug-eluting stents (DES) are often
used in complex patients, but there is limited knowledge about potential difference in
outcome between the zotarolimus-eluting Resolute and everolimus-eluting Xience V
stents in these patients.
Methods: We therefore analyzed the 2-year clinical outcome data of 1033 complex
TWENTE trial patients treated with second-generation everolimus-eluting Xience V
or zotarolimus-eluting Resolute stents. The primary endpoint of the TWENTE trial,
target vessel failure, was deﬁned as cardiac death, target vessel-related myocardial
infarction (MI), or target vessel revascularization (TVR).
Results: Among the 1033 complex patients, 529 (51.2%) were treated with Resolute
stents and 504 (48.8%) with Xience V. Patient and procedure-related characteristics
were similar between DES groups. After 2-year follow-up, clinical outcome was also
similar between DES groups. In patients treated with Resolute and Xience V, TVF
occurred in 12.1% and 12.3% of patients, respectively. In addition, DES groups did
not differ in cardiac death, MI, or TVR, the individual components of TVF.Conclusions: Complex patients treated with zotarolimus-eluting Resolute and ever-
olimus-eluting Xience V stents showed similar safety and efﬁcacy during 2-year
follow-up.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B55
